ANSWER: B

Rationale:

In the unliganded state, GR-α is maintained in the cytoplasm within a large chaperone complex whose components serve distinct and essential functions. HSP90 forms the structural core of the complex and holds the ligand-binding domain (LBD) in an open, high-affinity conformation that is required for efficient glucocorticoid binding; without HSP90, the LBD collapses and ligand binding is impaired. HSP70 is an earlier-binding chaperone that facilitates the initial folding of the newly synthesized GR and hands it off to HSP90. The co-chaperone p23 stabilizes the mature GR-HSP90 complex. The immunophilins FKBP51 and FKBP52 are large FK506-binding proteins that interact with HSP90 and regulate nuclear transport: FKBP51 retains the complex in the cytoplasm, while FKBP52 (which replaces FKBP51 upon ligand binding) facilitates dynein-mediated nuclear import. When a glucocorticoid binds the LBD, a conformational change displaces the chaperone complex, exposes the nuclear localization signal on the DNA-binding domain, and enables importin-α/β-mediated active transport into the nucleus. This entire sequence from ligand binding to nuclear entry occurs within minutes.

• Option A: Option A is incorrect — Importin-α and importin-β are the transport proteins that carry the activated GR-α complex into the nucleus after ligand binding; they are not part of the cytoplasmic retention complex and do not anchor the unliganded receptor at the nuclear pore.
• Option C: Option C is incorrect — I-κBα is the cytoplasmic inhibitor of NF-κB (nuclear factor kappa B), not of GR-α. I-κBα binds the p65/p50 NF-κB subunits and masks their nuclear localization signal; it has no direct role in GR-α cytoplasmic retention.
• Option D: Option D is incorrect — GR-α does not exist as a preformed homodimer in the cytoplasm. Homodimerization occurs in the nucleus after ligand-activated GR-α has been imported; the dimer then binds palindromic GRE sequences to drive transactivation. Cytoplasmic dimerization is not part of the normal GR activation pathway.
• Option E: Option E is incorrect — The 26S proteasome degrades ubiquitinated proteins and is involved in GR turnover after prolonged activation, but it does not function as a cytoplasmic retention complex for unliganded GR-α. Proteasomal association is not the mechanism by which GR-α is sequestered from the nucleus in the basal state.

ANSWER: D

Rationale:

Transrepression is the mechanism by which activated GR-α suppresses pro-inflammatory gene transcription without directly binding DNA at the target gene's promoter. The activated GR-α monomer physically interacts with the p65 (RelA) subunit of NF-κB through a direct protein-protein tethering interaction. This tethering prevents p65 from binding to its cognate κB response elements in the promoters of IL-1β, IL-2, IL-6, IL-8 (CXCL8), and TNF-α genes. GR-α similarly tethers to and inhibits AP-1 (a heterodimer of Fos and Jun family proteins), suppressing AP-1-driven transcription of matrix metalloproteinases and additional cytokine genes. A complementary transrepression mechanism involves GR-mediated recruitment of histone deacetylase 2 (HDAC2) to NF-κB-responsive promoters, reversing the histone acetylation that maintains chromatin in a pro-inflammatory open state. This transrepression pathway is considered the primary basis for the anti-inflammatory and immunosuppressive effects of corticosteroids and does not require GR homodimerization or direct GRE binding.

• Option A: Option A is incorrect — Negative GREs (nGREs) are specific DNA sequences at which GR monomers or dimers directly bind and suppress transcription. While nGREs do exist and contribute to GR-mediated repression at some genes, the classical transrepression of NF-κB-dependent cytokine genes occurs through the protein-protein tethering mechanism, not through GR binding to nGREs at those promoters. Additionally, GR binding to nGREs recruits corepressors, not acetyltransferases.
• Option B: Option B is incorrect — Corticosteroids do not directly inhibit JAK2 at its catalytic domain. JAK inhibition is the mechanism of action of janus kinase inhibitors (JAK inhibitors) such as ruxolitinib and tofacitinib, which are a distinct drug class. GR-mediated transrepression operates upstream through transcription factor interference, not through kinase active-site blockade.
• Option C: Option C is incorrect — While corticosteroids do upregulate IL-10 expression (a genuine anti-inflammatory feedback mechanism), the primary mechanism by which they suppress IL-1β, IL-6, and TNF-α transcription is NF-κB and AP-1 transrepression, not IL-10-mediated receptor competition. Furthermore, cytokine receptors are specific and do not share binding sites across unrelated cytokine families.
• Option E: Option E is incorrect — SOCS3 (suppressor of cytokine signaling 3) is indeed induced by corticosteroids and contributes to feedback inhibition of cytokine signaling. However, SOCS3 induction is a secondary, downstream mechanism. The primary mechanism of corticosteroid-mediated suppression of cytokine gene transcription is GR-mediated NF-κB and AP-1 transrepression, which operates directly at the gene promoter level and accounts for the broad suppression of multiple cytokine genes simultaneously.

ANSWER: A

Rationale:

Aspirin-exacerbated respiratory disease (AERD) occurs in susceptible individuals when COX inhibition by aspirin or other NSAIDs blocks prostaglandin E2 (PGE2) synthesis. PGE2 normally exerts a restraining influence on mast cell 5-LOX activity; when PGE2 production falls, the 5-LOX pathway is disinhibited and arachidonic acid (AA) is shunted into leukotriene synthesis, generating the cysteinyl leukotrienes (LTC4, LTD4, LTE4) that trigger bronchoconstriction. NSAIDs act downstream of phospholipase A2 (PLA2) and block only the COX pathway; the 5-LOX branch remains fully functional and is paradoxically enhanced when COX is suppressed. Corticosteroids act upstream of this branch point: by inducing annexin A1 (lipocortin-1), which inhibits cytosolic PLA2, they reduce the liberation of AA from membrane phospholipids. With less free AA available, substrate is simultaneously reduced for both the COX and 5-LOX pathways, preventing the compensatory surge in leukotriene synthesis that occurs with COX-only inhibition. This is the mechanistic basis for corticosteroids' effectiveness in AERD and in eosinophilic airway inflammation generally.

• Option B: Option B is incorrect — Corticosteroids do not directly block cysteinyl leukotriene receptors (CysLT1, CysLT2). Receptor antagonism is the mechanism of montelukast and zafirlukast (leukotriene receptor antagonists), which are a distinct drug class. Corticosteroids act upstream by reducing leukotriene synthesis, not by blocking the receptors through which leukotrienes act.
• Option C: Option C is incorrect — Corticosteroids do not directly inhibit COX-1 or COX-2 at their catalytic active sites. Active-site inhibition is the mechanism shared by all NSAIDs. Corticosteroids suppress COX-2 expression indirectly through transrepression of NF-κB, which reduces COX-2 gene transcription; this is a transcriptional mechanism, not a direct enzymatic inhibition, and it does not apply to COX-1, which is constitutively expressed and not NF-κB-dependent.
• Option D: Option D is incorrect — This option inverts the pharmacology. NSAIDs cause bronchoconstriction in AERD primarily by inhibiting COX-1 (which generates the PGE2 that restrains mast cell 5-LOX activity), not COX-2. Corticosteroids are not selective for either COX isoform at the protein level and do not spare COX-2 while blocking COX-1; rather, they suppress COX-2 gene expression through NF-κB transrepression while not targeting COX-1 transcriptionally.
• Option E: Option E is incorrect — While lipoxins are endogenous anti-inflammatory eicosanoids generated by 15-LOX and can oppose leukotriene actions, corticosteroids do not act primarily by upregulating 15-LOX expression. The established mechanistic explanation for corticosteroid efficacy upstream of the COX/LOX branch point is PLA2 inhibition through lipocortin-1 induction, not diversion of AA toward the lipoxin pathway via 15-LOX upregulation.

ANSWER: C

Rationale:

GR-β is produced by alternative splicing of the NR3C1 pre-mRNA at the 3′ end of exon 9, generating a receptor that shares the N-terminal transactivation domain (NTD) and DNA-binding domain (DBD) with GR-α but differs in its C-terminal ligand-binding domain (LBD): a distinct 15-amino-acid sequence replaces the last 50 amino acids of GR-α's LBD. This structural alteration in the LBD means that GR-β cannot bind glucocorticoids (the hormone-binding pocket is absent), cannot activate GRE-driven transcription, and lacks the activation function-2 (AF-2) surface required for coactivator recruitment. Despite these deficiencies, GR-β retains the ability to bind GRE sequences (through the shared DBD) and to interact with coactivators non-productively, effectively competing with GR-α for both the DNA and the coactivator pool. The result is dominant-negative inhibition: elevated GR-β displaces GR-α from GRE sites and sequesters coactivators, reducing glucocorticoid-driven transactivation and transrepression. Elevated GR-β to GR-α ratios have been identified in glucocorticoid-resistant asthma, steroid-resistant nephrotic syndrome, and rheumatoid arthritis, providing a molecular basis for clinical steroid resistance in these populations.

• Option A: Option A is incorrect — Casein kinase 2 (CK2) phosphorylation of GR-α has been described in some experimental contexts, but the clinically established mechanism of GR isoform-mediated steroid resistance involves GR-β as a dominant-negative inhibitor, not phosphorylation-mediated LBD blockade. CK2-mediated resistance is not a recognized clinical entity in the way that GR-β elevation is.
• Option B: Option B is incorrect — While oxidative stress can impair GR function through multiple mechanisms (including HDAC2 oxidation, which reduces GR-mediated HDAC2 recruitment in COPD), calpain-mediated cleavage of GR-α producing a truncated isoform that accelerates proteasomal degradation is not the established molecular mechanism of clinical steroid resistance linked to an elevated GR isoform ratio.
• Option D: Option D is incorrect — GR-γ is a real splice variant with an inserted arginine residue in the DBD that modestly alters DNA binding. However, GR-γ is not the isoform characteristically elevated in clinical steroid resistance, and it does not function as a dominant-negative inhibitor. GR-β is the dominant-negative splice variant associated with clinical resistance.
• Option E: Option E is incorrect — GR-α acetylation at lysine residues is involved in regulation of GR activity within the normal activation cycle (deacetylation by HDAC2 is required for efficient GR-mediated NF-κB suppression). However, acetylation does not convert GR-α into a constitutive repressor of its own target genes, and this mechanism does not describe the generation of a distinct isoform with an elevated ratio to GR-α.

ANSWER: E

Rationale:

Prednisone is a prodrug. It is administered as an 11-keto compound (with a ketone at carbon-11 of the steroid ring) and is pharmacologically inactive in this form. The hepatic enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is highly expressed in the liver, catalyzes the reduction of the 11-keto group to an 11β-hydroxyl, generating prednisolone — the pharmacologically active form that binds the glucocorticoid receptor (GR). In patients with normal hepatic function, this conversion is highly efficient, and prednisone and prednisolone are therapeutically interchangeable. However, in patients with severe hepatic disease (cirrhosis, fulminant hepatic failure), the reduced 11β-HSD1 activity in the damaged liver impairs this activation step, resulting in lower prednisolone plasma concentrations than expected for the administered prednisone dose. Prednisolone does not require this hepatic activation step because it already carries the 11β-hydroxyl group in its structure. Using prednisolone directly in patients with severe liver disease ensures that pharmacologically active drug is delivered reliably, avoiding the uncertainty of variable prodrug conversion.

• Option A: Option A is incorrect — Prednisone and prednisolone have essentially the same glucocorticoid and mineralocorticoid potency profile — they are the prodrug/active drug pair of the same steroid. Their mineralocorticoid activity is identical (both have a potency of approximately 0.8 relative to hydrocortisone) and is not the basis for the prescribing preference in liver disease.
• Option B: Option B is incorrect — The primary route of corticosteroid metabolism is hepatic CYP3A4 oxidation and conjugation, not renal sulfation. Prednisone does not accumulate through a biliary-renal sulfate mechanism; the clinical concern in liver disease is impaired 11β-HSD1-mediated activation of the prodrug to its active form, not accumulation of a toxic conjugate.
• Option C: Option C is incorrect — While hypoalbuminemia in cirrhosis does alter the protein binding of many drugs, the key pharmacokinetic concern with prednisone specifically is its incomplete conversion to active prednisolone due to reduced hepatic 11β-HSD1 activity, not a disproportionate increase in free fraction. Prednisolone does not avoid protein binding; it is actually more highly protein-bound than prednisone at physiological concentrations.
• Option D: Option D is incorrect — There is no clinically established pathway of intestinal glucuronidation that is specifically saturable for prednisone in cirrhotic patients, and prednisolone is not absorbed by lymphatic transport that bypasses intestinal metabolism. The distinction between these two agents in liver disease is entirely explained by the hepatic prodrug activation requirement.

ANSWER: B

Rationale:

Rifampin is the most potent inducer of CYP3A4 (cytochrome P450 3A4) encountered in clinical practice. By strongly upregulating CYP3A4 expression in both the liver and the intestinal wall through activation of the pregnane X receptor (PXR), rifampin markedly accelerates the oxidative metabolism of corticosteroids. This effect has been quantified in pharmacokinetic studies showing rifampin can reduce plasma corticosteroid concentrations by 50 to 75%, depending on the agent and the individual's baseline CYP3A4 induction response. For a patient with Addison disease whose adrenal cortex cannot generate any endogenous cortisol, the entire glucocorticoid supply comes from exogenous hydrocortisone replacement. If that supply is reduced by 50 to 75% due to CYP3A4 induction, the patient is effectively undertreated and can develop acute adrenal insufficiency (adrenal crisis), presenting with the classic features of cortisol deficiency: fatigue, nausea, vomiting, hypotension from loss of glucocorticoid-mediated vascular tone support, and hypoglycemia from loss of glucocorticoid-driven hepatic gluconeogenesis. Management requires increasing the hydrocortisone dose by two- to three-fold while rifampin is continued, or substituting an alternative antimicrobial regimen.

• Option A: Option A is incorrect — Rifampin is a potent CYP3A4 inducer, not an inhibitor. CYP3A4 inhibitors (azole antifungals, macrolides, ritonavir) increase corticosteroid plasma levels; CYP3A4 inducers like rifampin decrease them. Increased corticosteroid exposure from CYP3A4 inhibition would suppress residual adrenal function in patients with partial adrenal reserve, but that is the opposite of the mechanism operating here and would not explain an acute insufficiency presentation.
• Option C: Option C is incorrect — Rifampin does inhibit OATP1B1 and this is clinically relevant for drugs such as statins and some antibiotics. However, hydrocortisone is not a significant OATP1B1 substrate, and the predominant mechanism of rifampin-corticosteroid interaction is CYP3A4 induction causing accelerated systemic clearance, not hepatic uptake transporter inhibition.
• Option D: Option D is incorrect — Displacement from corticosteroid-binding globulin (CBG) is not a clinically significant mechanism of rifampin-hydrocortisone interaction. CBG displacement can transiently alter the free fraction of cortisol but this effect is rapidly equilibrated and does not produce the degree of plasma concentration reduction (50 to 75%) seen with CYP3A4 induction. Furthermore, the unbound fraction of cortisol is readily rebound upon redistribution and is not cleared in large quantities by glomerular filtration under physiological conditions.
• Option E: Option E is incorrect — Rifampin does not upregulate GR-β expression through an NF-κB-dependent mechanism. GR-β elevation as a cause of steroid resistance is a molecular mechanism described in certain inflammatory conditions such as steroid-resistant asthma and nephrotic syndrome; it is not a pharmacokinetic drug interaction. The clinical scenario described — acute presentation with hypotension and hypoglycemia after starting rifampin — is a pharmacokinetic interaction, not a receptor-level resistance phenomenon.

ANSWER: D

Rationale:

Fludrocortisone is a synthetic corticosteroid with an exceptionally potent mineralocorticoid profile: its mineralocorticoid potency is approximately 125 to 150 times that of hydrocortisone, making it the most potent mineralocorticoid agonist used clinically. Activation of the mineralocorticoid receptor (MR) in the renal collecting duct by fludrocortisone promotes sodium reabsorption and potassium excretion through upregulation of ENaC (epithelial sodium channel) and basolateral Na+/K+-ATPase expression. This effect is therapeutically employed to maintain sodium balance and blood pressure in patients with primary adrenal insufficiency (Addison disease, who cannot produce aldosterone) and in conditions such as orthostatic hypotension (including POTS, postural orthostatic tachycardia syndrome) where volume expansion and enhanced vascular tone are desired. Despite its high mineralocorticoid potency, fludrocortisone has only modest glucocorticoid potency (approximately 10 to 15 times hydrocortisone), which is insufficient for anti-inflammatory use. In the standard potency table, fludrocortisone stands apart from the other agents because its primary clinical role is mineralocorticoid replacement, not anti-inflammatory therapy, and no meaningful anti-inflammatory equivalent dose is defined for it.

• Option A: Option A is incorrect — The glucocorticoid potency of approximately 25 to 30 times hydrocortisone describes dexamethasone and betamethasone, not fludrocortisone. Dexamethasone, not fludrocortisone, is preferred for conditions requiring potent anti-inflammatory activity without mineralocorticoid effect, such as cerebral edema and GCA when dexamethasone-based dosing is used.
• Option B: Option B is incorrect — This statement precisely inverts fludrocortisone's pharmacological profile. Fludrocortisone has among the highest mineralocorticoid activity of any corticosteroid; it is not used in situations where mineralocorticoid effect must be minimized. Agents with zero mineralocorticoid activity include dexamethasone, betamethasone, and triamcinolone, which are preferred when sodium retention must be avoided.
• Option C: Option C is incorrect — The biological half-life of 36 to 54 hours applies to dexamethasone and betamethasone. Fludrocortisone has a biological half-life of approximately 12 to 36 hours. More importantly, fludrocortisone is used for its mineralocorticoid effect, and its dosing is guided by blood pressure and electrolyte response, not by half-life considerations for anti-inflammatory use.
• Option E: Option E is incorrect — Fludrocortisone is administered orally as a systemic agent — it is not a topical drug and is not contraindicated for systemic use. While the 9-alpha-fluorine substitution does enhance both glucocorticoid and mineralocorticoid receptor binding affinity (contributing to its potency), it does not cause irreversible receptor binding or cumulative toxicity. Irreversible receptor binding is not a property of any clinically used corticosteroid.

ANSWER: A

Rationale:

Dexamethasone is the corticosteroid of choice for vasogenic cerebral edema associated with brain tumors, metastases, and radiation necrosis. Two pharmacological features make it particularly suited to this indication. First, dexamethasone has essentially zero mineralocorticoid activity — its mineralocorticoid potency is negligible (approximately 0 relative to hydrocortisone), in contrast to hydrocortisone (potency 1) and prednisone (potency 0.8). Mineralocorticoid receptor activation in the kidney promotes sodium and water retention, which would increase intravascular volume and potentially worsen brain edema in a patient with compromised blood-brain barrier function; avoiding this effect is clinically important. Second, dexamethasone has a biological half-life of 36 to 54 hours, substantially longer than hydrocortisone (8 to 12 hours) or prednisone/prednisolone (12 to 36 hours). This prolonged biological activity, which reflects the duration of GR-driven transcriptional changes rather than the plasma half-life, permits convenient dosing (typically 4 mg every 6 hours for initial therapy, with flexibility for twice-daily dosing during maintenance) and provides sustained suppression of VEGF-related vascular permeability — the mechanism most responsible for the edema around tumor tissue.

• Option B: Option B is incorrect — While dexamethasone's lipophilicity does facilitate CNS penetration, the premise that it is the only corticosteroid to cross the blood-brain barrier is incorrect. Methylprednisolone, for example, also penetrates the CNS and is used for acute spinal cord injury and multiple sclerosis relapses. The preference for dexamethasone in cerebral edema is driven by its mineralocorticoid profile and biological half-life, not by unique BBB penetration that other agents lack.
• Option C: Option C is incorrect — Dexamethasone is not specifically FDA-approved for cerebral edema from glioblastoma based on comparative head-to-head survival trials versus other corticosteroids. Its preferential use is supported by clinical convention, case series, and mechanistic rationale rather than a formal randomized controlled trial demonstrating superiority over methylprednisolone or prednisone specifically in that indication. The statement about unique FDA approval based on survival trials is not accurate.
• Option D: Option D is incorrect — While dexamethasone does reduce VEGF expression in some tumor-associated cells through GR-mediated transcriptional mechanisms (including downregulation of HIF-1α-driven VEGF gene expression), this is a GR-dependent mechanism, not an antineoplastic effect independent of the glucocorticoid receptor. Dexamethasone is not classified as a cytostatic agent, and direct antineoplastic activity is not the basis for its use in cerebral edema management.
• Option E: Option E is incorrect — The plasma half-life of dexamethasone is approximately 3 to 4.5 hours, not 36 to 54 hours. The value of 36 to 54 hours refers to the biological half-life — the duration of GR-driven transcriptional effects, not the plasma concentration kinetics. The preference for dexamethasone over hydrocortisone is explained by mineralocorticoid profile and biological duration of action, not by plasma half-life matching the time course of tumor edema.

ANSWER: C

Rationale:

The standard anti-inflammatory potency table, anchored to hydrocortisone as the reference compound with an equivalent anti-inflammatory dose of 20 mg, defines the following equivalencies: hydrocortisone 20 mg = prednisone/prednisolone 5 mg = methylprednisolone 4 mg = triamcinolone 4 mg = dexamethasone/betamethasone 0.75 mg. This potency difference between prednisolone and methylprednisolone arises from methylprednisolone's slightly higher GR binding affinity and relative lack of mineralocorticoid activity; 4 mg of methylprednisolone produces approximately the same anti-inflammatory effect as 5 mg of prednisolone. Applying this conversion factor: 40 mg prednisolone ÷ 5 mg (prednisolone equivalent unit) × 4 mg (methylprednisolone equivalent unit) = 32 mg methylprednisolone. In practice, the oral-to-intravenous conversion for methylprednisolone is approximately 1:1, so the route change introduces no additional adjustment — the conversion is driven entirely by the different milligram potency between the two agents. The 32 mg dose would typically be administered as 32 mg IV daily or 16 mg IV twice daily in the ICU (intensive care unit) setting.

• Option A: Option A is incorrect — Dividing the prednisolone dose by four would yield 10 mg, which is an underestimate. This would represent a significant dose reduction and could result in undertreated asthma. The 5:4 prednisolone-to-methylprednisolone ratio means the methylprednisolone dose is 80% of the prednisolone dose, not 25%.
• Option B: Option B is incorrect — Methylprednisolone does not have the same milligram-for-milligram potency as prednisolone, so interval adjustment alone without dose recalculation would result in the wrong total daily dose. Administering 50 mg of methylprednisolone every 12 hours (100 mg/day) would substantially overshoot the equivalent of 40 mg prednisolone/day and carry a higher risk of corticosteroid adverse effects.
• Option D: Option D is incorrect — Methylprednisolone is not exactly twice as potent as prednisolone. The correct ratio is 5 mg prednisolone to 4 mg methylprednisolone, a modest 25% potency difference. Halving the prednisolone dose would yield 20 mg methylprednisolone, which significantly underdoses the patient relative to the intended anti-inflammatory effect.
• Option E: Option E is incorrect — Prednisolone and methylprednisolone do not have a 1:1 milligram-for-milligram equivalence. The potency table clearly establishes that 5 mg prednisolone = 4 mg methylprednisolone. Using a 1:1 conversion and administering 40 mg methylprednisolone would provide approximately 25% more anti-inflammatory potency than intended, equivalent to approximately 50 mg prednisolone.

ANSWER: E

Rationale:

Giant cell arteritis (GCA) is a granulomatous vasculitis of medium and large vessels, predominantly affecting the superficial temporal artery, ophthalmic artery, and posterior ciliary arteries. The most feared complication is permanent bilateral blindness from anterior ischemic optic neuropathy (AION), which occurs when inflammation occludes the posterior ciliary arteries supplying the optic nerve head. This complication can develop within hours to days of symptom onset and is irreversible once established. When the clinical presentation is consistent with GCA — age above 50, new headache, jaw claudication (pain with chewing due to ischemia of the masseter), tender or thickened temporal artery, and markedly elevated inflammatory markers (ESR above 50 mm/hr or CRP above 10 mg/L) — high-dose prednisone (40 to 60 mg/day) must be initiated immediately. Temporal artery biopsy remains the diagnostic gold standard and should be obtained urgently, but treatment must not wait for the result. The histologic findings of granulomatous inflammation with giant cells, lymphocytes, and macrophages in the media and adventitia persist for at least 2 weeks after corticosteroid initiation, preserving diagnostic yield even after therapy has begun. This is one of the most firmly established principles in rheumatological medicine: never delay GCA treatment pending biopsy when the clinical picture is compelling.

• Option A: Option A is incorrect — This option describes the opposite of the correct approach. Delaying corticosteroid therapy until histologic confirmation in a patient with compelling clinical features of GCA risks permanent ischemic vision loss. The guideline-recommended approach is to treat immediately and biopsy within 1 to 2 weeks; steroid initiation for 1 to 2 weeks does not materially compromise biopsy diagnostic yield.
• Option B: Option B is incorrect — Low-dose prednisone (7.5 mg/day) is entirely inadequate for GCA and would not suppress the large-vessel granulomatous inflammation responsible for vascular occlusion. The standard initial dose is 40 to 60 mg/day. Low-dose regimens at this level are used for polymyalgia rheumatica (PMR), which can coexist with GCA but does not carry the same vision-threatening risk.
• Option C: Option C is incorrect — Aspirin is not a first-line treatment for GCA; high-dose corticosteroids are the cornerstone of therapy. While low-dose aspirin (81 mg/day) is sometimes added as adjunctive therapy in GCA to reduce the risk of ischemic complications (small observational data), full-dose aspirin is not indicated and does not replace corticosteroids. COX inhibition is the mechanism of NSAIDs, which are not effective for the immunologically driven vasculitis of GCA.
• Option D: Option D is incorrect — While MRI with contrast can demonstrate vessel wall enhancement in GCA and is increasingly used as a diagnostic tool, it is not a substitute for prompt therapeutic intervention in a patient with high clinical probability of GCA. Obtaining MRI before starting treatment would introduce a dangerous delay. Moreover, MRI does not provide the histologic confirmation that definitively establishes the diagnosis; it can support but not replace temporal artery biopsy as the gold standard.

ANSWER: B

Rationale:

Eosinophils have a relatively short circulating lifespan of approximately 8 to 18 hours and depend on continuous cytokine signaling to survive in tissues beyond this period. The two most critical eosinophil survival factors are interleukin-5 (IL-5) and granulocyte-macrophage colony-stimulating factor (GM-CSF). IL-5 is produced primarily by Th2 (T helper 2) lymphocytes and ILC2 (type 2 innate lymphoid cells) and drives eosinophil maturation in the bone marrow, promotes their egress into the bloodstream, and extends their survival in inflamed tissues by activating the JAK2/STAT5 (signal transducer and activator of transcription 5) signaling pathway, which upregulates anti-apoptotic proteins including BCL-2 and BCL-XL. GM-CSF acts similarly and is produced by epithelial cells, T cells, mast cells, and eosinophils themselves in an autocrine loop. Corticosteroids, through GR-mediated transrepression of NF-κB and AP-1, broadly suppress the transcription of both IL-5 and GM-CSF. When these survival signals are withdrawn from tissue eosinophils, the anti-apoptotic protein balance shifts toward pro-apoptotic mediators (including Bax), and programmed cell death follows within hours. This mechanism explains the rapid fall in blood and tissue eosinophilia observed after a single dose of corticosteroid in eosinophilic airway disease.

• Option A: Option A is incorrect — While corticosteroids can influence intracellular apoptotic pathways, there is no established eosinophil-specific GR isoform in granule membranes that directly activates caspase-3 through a membrane receptor pathway. The primary mechanism of corticosteroid-induced eosinophil apoptosis is indirect — mediated through suppression of survival-factor cytokine gene transcription rather than through direct caspase activation via a specialized isoform.
• Option C: Option C is incorrect — Corticosteroids do not primarily act by upregulating Fas ligand expression on T lymphocytes to activate the eosinophil Fas pathway. While Fas-FasL interactions can induce eosinophil apoptosis experimentally, this is not the predominant mechanism by which pharmacological corticosteroid doses reduce eosinophilia clinically. The established mechanism centers on IL-5 and GM-CSF suppression.
• Option D: Option D is incorrect — Non-genomic GR signaling through PI3K/Akt inhibition in eosinophils has been investigated experimentally, but it is not the primary mechanism underlying the clinically observed eosinophil-depleting effect of corticosteroids. The dominant mechanism is genomic — suppression of IL-5 and GM-CSF gene transcription through NF-κB and AP-1 transrepression — which operates at the level of the cytokine-producing cells (Th2 lymphocytes and epithelial cells), not within the eosinophil directly.
• Option E: Option E is incorrect — While corticosteroids do suppress CCR3 expression and eotaxin production (reducing eosinophil tissue recruitment), this mechanism addresses trafficking, not survival-factor withdrawal. The question asks specifically about the mechanism by which corticosteroids promote eosinophil apoptosis, which is best explained by IL-5 and GM-CSF suppression rather than by CCR3-mediated retention of eosinophils in the bone marrow.

ANSWER: A

Rationale:

Corticosteroid-induced neutrophilia is a well-recognized and expected pharmacological effect that can reach 2- to 3-fold increases in the absolute neutrophil count within 4 to 6 hours of administration. Two distinct mechanisms contribute simultaneously. First, demargination: under normal conditions, approximately half of the total peripheral neutrophil pool is loosely adherent to vascular endothelium through ICAM-1 (intercellular adhesion molecule-1) and E-selectin interactions on endothelial cells and complementary surface integrins (LFA-1, Mac-1) on neutrophils. Corticosteroids downregulate ICAM-1 and E-selectin expression on endothelial cells, reducing adhesion and releasing the marginated pool into the circulating blood within hours. Second, corticosteroids trigger release of the bone marrow storage pool, which normally contains a reserve of mature neutrophils 10 to 20 times the circulating count. The critical clinical insight is that this elevated circulating neutrophil count does not reflect enhanced host defense at the tissue level: corticosteroids simultaneously suppress neutrophil tissue infiltration by reducing chemokine production (IL-8/CXCL8 is suppressed through NF-κB transrepression) and downregulating neutrophil surface adhesion receptors. A patient on high-dose corticosteroids may have a markedly elevated WBC with impaired ability to deliver functional neutrophils to a site of infection — a pharmacological neutrophilia that masks a compromised innate immune response.

• Option B: Option B is incorrect — While corticosteroids can modestly influence hematopoietic cytokine expression in some contexts, direct GRE-driven upregulation of G-CSF (granulocyte colony-stimulating factor) is not the established mechanism of corticosteroid-induced neutrophilia. The onset of bone marrow-driven granulopoiesis takes days to weeks; the rapid 4- to 6-hour onset of corticosteroid neutrophilia is explained by demargination and storage pool release, not by increased production.
• Option C: Option C is incorrect — While catecholamines (epinephrine) do cause demargination through beta-2 adrenergic receptor activation on neutrophils, corticosteroid-induced demargination is a direct effect of corticosteroids on endothelial adhesion molecule expression (ICAM-1, E-selectin downregulation), independent of adrenal medullary epinephrine levels. Corticosteroids do not suppress adrenal medullary catecholamine secretion as their primary mechanism here.
• Option D: Option D is incorrect — Corticosteroids do prolong neutrophil survival by delaying apoptosis, and this contributes modestly to elevated circulating counts. However, this mechanism operates over days, not within the 4- to 6-hour window in which the dramatic neutrophilia is observed clinically. The rapid, large-magnitude neutrophilia seen acutely is explained by demargination and bone marrow pool release, not by apoptosis delay alone.
• Option E: Option E is incorrect — Stress leukocytosis from the inflammatory disease itself is a contributing factor in some hospitalized patients, but corticosteroids unambiguously cause neutrophilia through the direct mechanisms described above. Attributing the neutrophilia entirely to the underlying disease and ordering infection workup without recognizing the expected pharmacological effect of high-dose prednisone would lead to unnecessary investigations in this afebrile patient.

ANSWER: D

Rationale:

The favorable therapeutic window of ICS rests on two complementary pharmacokinetic features working in concert. The first is local drug delivery: inhalation deposits drug directly onto the inflamed airway mucosa, achieving bronchial mucosal concentrations substantially higher than would be generated by any oral dose that avoids systemic toxicity. The lung deposition fraction varies by device and technique (approximately 10 to 40% for metered-dose inhalers with spacer use) — the remainder is deposited in the oropharynx and swallowed. The second and more important feature is first-pass hepatic metabolism: the systemically absorbed fraction (from both pulmonary absorption and gastrointestinal absorption of the swallowed oropharyngeal fraction) enters the hepatic portal circulation, where CYP3A4-mediated metabolism rapidly inactivates most ICS before they can reach systemic tissues. Fluticasone propionate and fluticasone furoate exemplify this principle with essentially zero oral bioavailability — near-complete first-pass hepatic extraction means the swallowed fraction contributes virtually nothing to systemic exposure. Budesonide undergoes approximately 90% first-pass metabolism. Ciclesonide adds a further safety layer: it is a prodrug activated by esterases in the lung to the active form des-ciclesonide, with the prodrug form inactivated hepatically without receptor activity. The combination of targeted local delivery and rapid systemic clearance allows ICS to achieve airway anti-inflammatory efficacy comparable to moderate-dose systemic therapy with a markedly reduced systemic side effect burden.

• Option A: Option A is incorrect — ICS formulations are engineered to deliver small particles (typically 1 to 5 micrometers for optimal lower airway deposition); large particles above 10 micrometers impact primarily in the oropharynx and central airways and are swallowed. The therapeutic advantage does not depend on slow absorption from large-particle deposits — it depends on the pharmacokinetic features of first-pass metabolism described above.
• Option B: Option B is incorrect — ICS generally have high or very high GR binding affinities — fluticasone propionate, mometasone, and ciclesonide (active form) have receptor binding affinities that exceed prednisolone. The therapeutic advantage is not explained by lower receptor affinity; it is pharmacokinetic (first-pass extraction), not pharmacodynamic (receptor binding).
• Option C: Option C is incorrect — ICS are lipophilic compounds (high lipophilicity is required for membrane penetration and efficient GR binding). They readily cross lipid cell membranes and are absorbed into the systemic circulation from both the lung and the gastrointestinal tract — the therapeutic advantage comes from rapid hepatic first-pass inactivation of this absorbed fraction, not from an inability to cross membranes. There is no membrane-bound GR isoform that exclusively mediates ICS effects.
• Option E: Option E is incorrect — Corticosteroids do not bind the GR covalently. All clinically used corticosteroids, including ICS, bind the GR reversibly through non-covalent hydrophobic and hydrogen-bonding interactions in the ligand-binding pocket. Covalent modification of cysteine residues is not a mechanism of any approved corticosteroid.

ANSWER: C

Rationale:

The threshold for clinically significant HPA axis suppression is most reliably defined by two parameters: the daily dose and the duration of treatment. The widely cited and clinically established threshold is prednisone (or equivalent) greater than 20 mg/day for more than 3 weeks. At this dose-duration combination, ACTH levels fall substantially due to negative feedback at the hypothalamic level (reduced CRH pulsatility) and pituitary level (reduced ACTH responsiveness to CRH), and the adrenal cortex begins to lose its ability to mount the 3- to 5-fold cortisol increase required to survive major physiological stress. However, the threshold is not absolute: prolonged use of even low doses (for example, prednisone 5 to 10 mg/day for 12 or more months) can produce significant suppression, and individual variability is substantial. Dexamethasone deserves special mention: its biological half-life of 36 to 54 hours means that even once-daily dosing at seemingly modest doses produces sustained, nearly continuous GR occupancy at the hypothalamus and pituitary, making it more likely to cause HPA suppression than an agent with a shorter biological half-life at equivalent anti-inflammatory doses. This is one reason dexamethasone is not preferred for chronic anti-inflammatory use despite its high potency and low mineralocorticoid activity.

• Option A: Option A is incorrect — Seven days of any dose of prednisone does not reliably produce clinically significant HPA axis suppression. Short courses of up to 2 to 3 weeks at doses below 20 mg/day are generally considered safe to discontinue without a formal taper, precisely because suppression at this dose-duration combination is unlikely to be clinically relevant. The 7-day threshold vastly overestimates the risk for most clinical scenarios.
• Option B: Option B is incorrect — This option substantially underestimates the risk threshold. Clinically significant HPA axis suppression regularly occurs at doses in the 20 to 40 mg/day range when sustained for more than 3 weeks; 60 mg/day is not the lower boundary of risk. Waiting for doses above 60 mg/day before counseling patients about HPA suppression would leave many patients at risk of adrenal crisis during stress without appropriate precautions.
• Option D: Option D is incorrect — While cumulative dose is a contributing factor to HPA suppression, daily dose and duration are the more clinically actionable and better-validated predictors. The concept of a specific cumulative dose threshold (such as 1,000 mg prednisone-equivalent) is not a standard clinical guideline parameter. A patient who received 500 mg over 25 days (20 mg/day) would be at risk; a patient who received the same 500 mg as a single pulse dose would not.
• Option E: Option E is incorrect — While morning dosing does reduce HPA axis suppression compared to evening or split dosing (by overlapping with rather than replacing the natural cortisol nadir that normally triggers CRH pulsatility), it does not eliminate HPA suppression at doses above 20 mg/day for more than 3 weeks. Morning dosing is a harm-reduction strategy, not a guarantee against suppression. Furthermore, exogenous glucocorticoids are pharmacologically identical to endogenous cortisol at the hypothalamic GR level and suppress the axis regardless of timing at sufficiently high doses.

ANSWER: E

Rationale:

Secondary adrenal insufficiency (SAI) resulting from exogenous corticosteroid suppression of the hypothalamic-pituitary-adrenal (HPA) axis differs from primary adrenal insufficiency (Addison disease) in two clinically important ways, both explained by the mechanism of the adrenal failure. In Addison disease, the adrenal cortex itself is destroyed, eliminating production of both cortisol and aldosterone; the pituitary compensates by massively increasing ACTH secretion (and pro-opiomelanocortin (POMC)-derived peptides including alpha-MSH, which stimulates melanocortin-1 receptors in skin melanocytes, causing hyperpigmentation). In SAI from corticosteroid withdrawal, the adrenal cortex is structurally intact but atrophied from disuse; the defect is insufficient ACTH drive from the suppressed pituitary. Critically, aldosterone secretion is controlled primarily by the renin-angiotensin-aldosterone system (RAAS) — specifically angiotensin II and potassium — not by ACTH. Therefore, when ACTH falls (as in SAI), aldosterone production continues normally, maintaining sodium reabsorption and potassium excretion through the mineralocorticoid receptor (MR) in the collecting duct. The clinical consequence is that patients with SAI do not develop the salt wasting, hyperkalemia, or hypovolemia characteristic of Addison disease. They also do not develop hyperpigmentation because ACTH levels are low (suppressed), not high — there is no excess POMC-derived MSH to stimulate melanocytes.

• Option A: Option A is incorrect — This option correctly identifies the hyperpigmentation mechanism (ACTH-related MSH co-secretion) but misattributes it to "permanent" ACTH suppression by exogenous corticosteroids. In reality, ACTH secretion does recover after corticosteroid withdrawal (the HPA axis eventually recovers), and the normal sodium and potassium in this patient reflect preserved aldosterone production through RAAS, not permanent ACTH suppression. The statement also incorrectly implies electrolytes would be abnormal in SAI.
• Option B: Option B is incorrect — Aldosterone deficiency is not the mechanism of SAI from corticosteroid withdrawal. Because aldosterone is regulated by the RAAS rather than ACTH, aldosterone production is preserved in SAI regardless of renal tubular status. The renin-angiotensin system does not compensate for a mineralocorticoid deficit through direct sodium retention — it regulates aldosterone secretion normally in the intact adrenal cortex.
• Option C: Option C is incorrect — This option describes the opposite of the correct clinical picture. SAI from corticosteroid withdrawal does not mimic primary adrenal insufficiency for the reasons described above. The preserved electrolytes and absent hyperpigmentation in this patient are characteristic of SAI, not primary adrenal medullary insufficiency (which would cause catecholamine deficiency presenting differently, primarily as hypoglycemia and loss of adrenergic stress response).
• Option D: Option D is incorrect — GR signaling is not "completely restored immediately" upon corticosteroid withdrawal. The reason symptoms occur is precisely because endogenous cortisol production has been suppressed and cannot recover quickly enough to meet physiological needs. The symptoms described — fatigue, nausea, orthostatic hypotension — reflect genuine glucocorticoid deficiency, not a receptor upregulation withdrawal syndrome. HPA axis recovery typically takes weeks to months, not hours.

ANSWER: B

Rationale:

This patient has been on prednisone 25 mg/day — above the 20 mg/day threshold — for 5 months, well beyond the 3-week duration threshold for HPA axis suppression. His adrenal cortex has atrophied due to sustained ACTH suppression and cannot generate the 3- to 5-fold increase in cortisol output (from approximately 8 to 10 mg/day to 75 to 150 mg/day) required to survive significant physiological stress such as a febrile illness with vomiting. Vomiting is a critical special circumstance: it makes the oral route unavailable, and without parenteral administration of glucocorticoid, the patient is at imminent risk of adrenal crisis. Adrenal crisis is a life-threatening emergency presenting with progressive hypotension, hypoglycemia, nausea, vomiting, and altered consciousness, which can rapidly progress to cardiovascular collapse and death if untreated. The standard emergency protocol for patients on chronic supraphysiological corticosteroids who cannot take oral medications is injection of hydrocortisone 100 mg intramuscularly (IM), followed by emergency medical evaluation. Patients at risk should be prescribed an emergency hydrocortisone injection kit (prefilled syringe) and trained in its administration (or have a family member trained) as part of routine sick day counseling at the time of initiating long-term corticosteroid therapy.

• Option A: Option A is incorrect — This option is dangerously incorrect. Months of corticosteroid therapy at 25 mg/day reliably suppresses the HPA axis. The adrenal gland in this patient cannot produce sufficient cortisol to cover even moderate physiological stress. Vomiting with inability to take oral medications during an acute illness is precisely the situation in which adrenal crisis can develop within hours without corticosteroid supplementation.
• Option C: Option C is incorrect — Waiting 6 hours before seeking care when a patient with known HPA suppression is vomiting and cannot take oral medications is inappropriate. The inability to absorb oral corticosteroid begins immediately when vomiting starts; there is no safe 6-hour grace window for a patient who has been on 25 mg/day prednisone for 5 months. Emergency parenteral administration should be initiated promptly, not after a defined waiting period.
• Option D: Option D is incorrect — Attempting oral absorption through dissolved tablets during active vomiting is unreliable. Even if partial absorption occurs, the amount absorbed during active emesis is unpredictable and insufficient to guarantee protection against adrenal crisis. The correct approach when the oral route is unavailable is to switch immediately to parenteral administration — not to modify the oral route.
• Option E: Option E is incorrect — Relying on residual systemic levels from a dose taken 12 hours ago is insufficient for a patient with complete HPA suppression who faces an ongoing physiological stress. Prednisone's biological half-life is 12 to 36 hours, meaning biological effects are waning by 12 hours after dosing; with active vomiting preventing the next dose, systemic glucocorticoid cover will continue to fall while physiological demand is rising due to the acute illness.

ANSWER: D

Rationale:

Alternate-day prednisone therapy is the dosing modification most effective at reducing HPA axis suppression while preserving anti-inflammatory efficacy. The rationale relies on the difference between prednisone's plasma half-life (approximately 60 minutes) and its biological half-life (12 to 36 hours). When prednisone is given as a double dose every 48 hours (for example, 20 mg every other day instead of 10 mg daily), the plasma concentration and GR occupancy in hypothalamic and pituitary cells fall substantially during the 48-hour interval — more specifically, a window of approximately 24 hours of low corticosteroid exposure occurs during each cycle. During this low-exposure window, pituitary corticotrophs partially recover ACTH responsiveness, and the adrenal cortex receives some ACTH stimulation, maintaining partial steroidogenic capacity. This contrasts with daily dosing, in which GR occupancy at the hypothalamus and pituitary is maintained almost continuously, producing more complete and sustained suppression. Alternate-day therapy preserves anti-inflammatory efficacy in many conditions — particularly those driven by eosinophils and lymphocytes, whose biological responses are more sustained than those of other leukocytes — but is less effective for conditions requiring continuous suppression, such as giant cell arteritis. Prednisone and prednisolone are the only corticosteroids truly suited to alternate-day regimens because of their intermediate biological half-lives; dexamethasone, with a 36 to 54 hour biological half-life, provides no off-day window even with alternate-day dosing.

• Option A: Option A is incorrect — Evening dosing of prednisone is specifically associated with greater HPA axis suppression, not less. The morning cortisol surge is the primary driver of the natural daily cortisol peak; evening dosing provides peak corticosteroid levels during the trough of endogenous cortisol production, more effectively suppressing the nocturnal CRH/ACTH rise that normally triggers the morning cortisol surge. Evening dosing is sometimes used therapeutically in conditions such as congenital adrenal hyperplasia where suppression of nocturnal ACTH-driven androgen production is the goal.
• Option B: Option B is incorrect — Split dosing spreads the corticosteroid effect more evenly throughout the day, producing lower peaks and higher troughs of GR occupancy than once-daily dosing. This provides more continuous GR occupancy at the hypothalamus and pituitary — which worsens HPA suppression compared to once-daily morning dosing, not improves it. Split dosing is not a strategy to reduce HPA suppression.
• Option C: Option C is incorrect — Morning dosing of prednisone does reduce HPA axis suppression compared to evening or split dosing and is the standard recommendation for chronic corticosteroid therapy. However, the question asks which modification reduces HPA suppression more effectively than any other timing adjustment, and alternate-day dosing surpasses once-daily morning dosing in this regard by providing the 24-hour low-exposure window that morning-only daily dosing does not.
• Option E: Option E is incorrect — Weekly pulsed oral dosing is not a recognized standard regimen for managing chronic inflammatory diseases with oral corticosteroids, and it would not provide the continuous anti-inflammatory suppression needed for conditions such as nephrotic syndrome, rheumatoid arthritis, or autoimmune disease. This is not an established clinical dosing modification.

ANSWER: A

Rationale:

The role of ICS in COPD has been substantially refined over the past decade by both clinical trials and biomarker research. Blood eosinophil count has emerged as the most validated and clinically accessible predictor of ICS responsiveness in COPD. Large analyses from the FLAME, IMPACT, and ETHOS trials have shown that patients with blood eosinophil counts above 300 cells/μL receive the greatest exacerbation reduction benefit from triple inhaled therapy (ICS + LABA + LAMA (long-acting muscarinic antagonist)), while patients with low counts (below 100 cells/μL) derive minimal or no exacerbation benefit from ICS. This is thought to reflect the underlying biology: eosinophil-driven airway inflammation is steroid-sensitive (via the eosinophil apoptosis and IL-5 suppression mechanisms), while neutrophil-dominant COPD inflammation is relatively steroid-resistant. A critical counterbalancing consideration is that ICS use in COPD specifically increases the risk of pneumonia — a risk that does not apply to the same degree in asthma and is not fully offset in patients with low eosinophil counts. The WISDOM trial, meanwhile, showed that ICS can be withdrawn from stable COPD patients without increasing exacerbations when dual bronchodilator therapy is maintained — but only in patients with low eosinophil counts, validating the biomarker-guided approach further.

• Option B: Option B is incorrect — Fractional exhaled nitric oxide (FeNO) is a validated biomarker for eosinophilic airway inflammation and ICS responsiveness in asthma, but it has not replaced blood eosinophil count in COPD guidelines. Current GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines use blood eosinophil count as the recommended biomarker for ICS decision-making in COPD. COPD pathophysiology is distinct from asthma and does not universally respond to ICS in a Th2-driven manner.
• Option C: Option C is incorrect — Sputum neutrophilia is characteristic of COPD pathophysiology and is associated with steroid resistance, not steroid responsiveness. Neutrophilic COPD inflammation is driven by innate immune pathways and oxidative stress mechanisms that are less responsive to GR-mediated transrepression of NF-κB than eosinophilic inflammation. High sputum neutrophil count does not predict ICS benefit in COPD; the opposite is more accurate.
• Option D: Option D is incorrect — The WISDOM trial reached the opposite conclusion to what this option states. WISDOM showed that ICS could be withdrawn from stable COPD patients without increasing exacerbations when dual bronchodilator therapy was continued — in patients with low eosinophil counts specifically. ICS are not recommended as first-line monotherapy for all exacerbation-prone COPD patients; the current standard is dual or triple bronchodilator therapy with ICS added based on biomarker-guided criteria.
• Option E: Option E is incorrect — The TORCH trial showed a trend toward (but did not reach statistical significance for) reduced all-cause mortality with fluticasone-salmeterol combination therapy compared to placebo. ICS are not contraindicated in COPD and are guideline-recommended in specific patient populations (frequent exacerbators with high eosinophil counts). Current GOLD guidelines incorporate ICS as a component of triple inhaled therapy in the appropriate patient population.

ANSWER: C

Rationale:

Corticosteroids suppress prostaglandin synthesis through two mechanistically distinct and complementary pathways. The first (the lipocortin-1/PLA2 pathway, covered in an earlier question) operates upstream by reducing arachidonic acid (AA) release, limiting substrate for all eicosanoid synthesis. The second operates at the gene transcription level: through the transrepression of NF-κB and AP-1, GR-α prevents these transcription factors from binding their response elements in the promoters of inducible COX-2 and inducible nitric oxide synthase (iNOS) genes. COX-2 is the inducible isoform of cyclooxygenase whose expression is driven by cytokines (IL-1β, TNF-α), LPS (lipopolysaccharide), and other inflammatory signals through NF-κB; its suppression at the gene level reduces inflammatory prostaglandin output even when substrate (AA) is present. This is distinct from NSAID action: NSAIDs inhibit the COX enzyme protein already present in cells but do not reduce COX-2 gene expression. The simultaneous suppression of iNOS reduces nitric oxide (NO) generation by activated macrophages and endothelial cells, attenuating NO-mediated vasodilation, increased vascular permeability, and macrophage cytotoxic activity. This dual gene-silencing mechanism, working alongside the upstream lipocortin-1 pathway, accounts for the greater overall anti-inflammatory potency of corticosteroids compared to any NSAID.

• Option A: Option A is incorrect — Corticosteroids do not bind to the COX-2 active site or inhibit COX enzyme activity directly. Competitive or non-competitive enzyme inhibition is the mechanism of NSAIDs (aspirin irreversibly acetylates COX-1 and COX-2 at serine-530; other NSAIDs competitively block the arachidonic acid channel). GR-mediated effects on COX-2 are transcriptional, not enzymatic.
• Option B: Option B is incorrect — While GRE-driven induction of 15-PGDH does contribute to corticosteroid-mediated reduction of PGE2 in some experimental models, this is not the established second mechanism by which corticosteroids independently suppress prostaglandin generation at the gene level in the clinical pharmacology literature. The primary gene-level mechanism is NF-κB/AP-1-mediated suppression of COX-2 transcription, not acceleration of PGE2 catabolism.
• Option D: Option D is incorrect — Corticosteroids do not induce inhibitors of mPGES-1 (microsomal prostaglandin E synthase-1) through GRE-driven transactivation as their primary second mechanism of prostaglandin suppression. While mPGES-1 inhibition is under investigation as a therapeutic target (to selectively reduce PGE2 while sparing prostacyclin and thromboxane), this is not an established mechanism of action of currently used corticosteroids.
• Option E: Option E is incorrect — Corticosteroids do not form stable GR-COX-2 cytoplasmic protein complexes that sequester COX-2 protein from endoplasmic reticulum membranes. GR-mediated effects on COX-2 are entirely at the transcriptional level (reducing mRNA synthesis through NF-κB transrepression), not through direct physical interaction with the COX-2 enzyme protein in the cytoplasm.

ANSWER: E

Rationale:

This patient has iatrogenic Cushing syndrome caused by a pharmacokinetic drug interaction between ritonavir and inhaled fluticasone propionate. Fluticasone propionate is extensively metabolized by CYP3A4; its oral bioavailability is essentially zero under normal circumstances because near-complete first-pass hepatic CYP3A4 extraction inactivates the swallowed oropharyngeal fraction before it reaches systemic circulation, and the pulmonary-absorbed fraction is also rapidly cleared. Ritonavir is among the most potent CYP3A4 inhibitors available — it irreversibly or quasi-irreversibly inhibits CYP3A4 as a mechanism-based inhibitor (suicide inhibitor). By blocking first-pass hepatic and intestinal CYP3A4, ritonavir transforms fluticasone from an effectively non-systemic drug into one with significant systemic exposure. The resulting elevated systemic fluticasone levels activate GR throughout the body, producing the classic features of glucocorticoid excess (central obesity, moon facies, purple striae, easy bruising from skin thinning) and suppress the HPA axis through negative feedback at the hypothalamus and pituitary — explaining the undetectable ACTH and low morning cortisol. This interaction is well-documented and clinically important: HIV-positive patients on ritonavir-containing regimens who receive inhaled or injected corticosteroids (particularly fluticasone and triamcinolone) are at risk for iatrogenic Cushing syndrome and secondary adrenal insufficiency that can become life-threatening if the ICS is abruptly discontinued.

• Option A: Option A is incorrect — Ritonavir is an HIV protease inhibitor that inhibits CYP3A4; it does not bind or activate the glucocorticoid receptor. It is not a GR agonist and does not cause hypercortisolism directly. The syndrome described is exogenous glucocorticoid excess from impaired fluticasone clearance, not endogenous cortisol overproduction.
• Option B: Option B is incorrect — Fluticasone propionate does not induce CYP3A4 expression. CYP3A4 inducers include rifampin, carbamazepine, and phenytoin; fluticasone is a CYP3A4 substrate, not an inducer. There is no clinical or pharmacological mechanism by which inhaled fluticasone would increase endogenous cortisol metabolism in a way that produces a paradoxical clinical appearance of cortisol excess.
• Option C: Option C is incorrect — 11β-HSD2 inhibition causing pseudoaldosteronism (apparent mineralocorticoid excess) is the mechanism of licorice toxicity and carbenoxolone. Ritonavir does not inhibit 11β-HSD2. Furthermore, the clinical syndrome described — central obesity, moon facies, striae, easy bruising, undetectable ACTH, low cortisol — is glucocorticoid excess (Cushing syndrome), not mineralocorticoid excess (which would present with hypertension, hypokalemia, and edema without the cushingoid features).
• Option D: Option D is incorrect — Fluticasone does not cause progressive auto-inhibition of CYP3A4. CYP3A4 auto-induction or auto-inhibition is not a pharmacological property of fluticasone. The interaction is unidirectional: ritonavir inhibits CYP3A4, impairing fluticasone clearance; fluticasone does not modify CYP3A4 over time.

ANSWER: B

Rationale:

GR signaling was long thought to be exclusively genomic — mediated by the transcriptional activation or repression of target genes through DNA binding or transcription factor tethering. However, certain corticosteroid effects occur too rapidly for transcriptional mechanisms (which require hours for mRNA transcription, translation, and protein accumulation) and must be explained by non-genomic pathways. Non-genomic GR signaling encompasses several rapid mechanisms. First, membrane-associated GR: a fraction of cellular GR is associated with the plasma membrane or caveolae, where it can interact with signaling proteins independently of nuclear translocation. Second, upon ligand binding in the cytoplasm, the conformational change that dissociates the HSP90/HSP70/p23 complex simultaneously releases signaling proteins that were co-chaperoned in the complex — including Src kinase and PI3K subunits — which are then free to activate downstream kinase cascades within seconds to minutes. Third, cytoplasmic GR can directly interact with and modulate MAPK pathway activity non-transcriptionally. These rapid non-genomic mechanisms contribute to the acute anti-inflammatory effects observed with high-dose IV corticosteroids, including rapid reduction in vascular permeability, rapid effects on leukocyte signaling, and the vascular stabilizing effects observed in septic shock at high doses. The relative contribution of non-genomic versus genomic mechanisms depends on dose and context, but non-genomic effects are disproportionately prominent at the suprapharmacological concentrations achieved by high-dose IV bolus administration.

• Option A: Option A is incorrect — Saturating CBG (corticosteroid-binding globulin) increases the free fraction of drug and enhances tissue delivery — this is a relevant pharmacokinetic consideration at high doses — but it does not compress the transcriptional latency of genomic GR signaling from hours to minutes. Genomic mechanisms require time for mRNA transcription and protein synthesis regardless of receptor occupancy levels or corepressor saturation.
• Option C: Option C is incorrect — Corticosteroids do not acutely activate membrane-bound mineralocorticoid receptors (MR) on vascular endothelium to trigger ENaC opening as a mechanism of their rapid effects. MR-mediated regulation of ENaC is a genomic, aldosterone-driven mechanism in the kidney collecting duct that takes hours. Vascular permeability reduction by high-dose corticosteroids is mediated through non-genomic GR kinase signaling and through rapid effects on leukocyte adhesion, not through osmotic ENaC-mediated mechanisms.
• Option D: Option D is incorrect — At physiological and pharmacological concentrations, corticosteroids do not directly inhibit PLA2 enzyme activity competitively. The established mechanism of PLA2 inhibition by corticosteroids is through GRE-driven induction of lipocortin-1 (annexin A1), a protein that requires transcription and translation — typically 4 to 6 hours. Direct enzymatic inhibition of PLA2 active sites is not the mechanism, and bolus IV dosing does not achieve concentrations relevant for non-specific enzyme inhibition.
• Option E: Option E is incorrect — There is no established G-protein-coupled corticosteroid membrane receptor that generates cAMP to inactivate NF-κB p65 via phosphorylation within minutes. The cAMP/protein kinase A pathway can modulate NF-κB activity in certain contexts, but this is not the accepted mechanism of rapid corticosteroid effects. The described receptor and mechanism are not pharmacologically established for corticosteroids.

ANSWER: D

Rationale:

Corticosteroid tapering must balance two competing risks: relapse of the underlying inflammatory disease if the dose falls too rapidly, and prolonged HPA axis suppression if supraphysiological doses are maintained unnecessarily. For courses longer than 3 weeks, a structured taper is required. The standard approach divides the taper into two phases. In the first phase (supraphysiological to physiological range), relatively larger weekly reductions are possible — for example, reducing by 5 to 10 mg per week from 40 mg/day down to the physiological replacement range of 5 to 7.5 mg/day. This range corresponds to the normal daily cortisol production rate of approximately 8 to 10 mg of cortisol equivalents per day; below this threshold, exogenous prednisone is no longer supplementing above-normal cortisol levels but is instead filling the gap left by the suppressed adrenal axis. In the second phase (at and below the physiological replacement range), the pace slows dramatically — typically 1 mg per week or 1 mg every 2 weeks — because the HPA axis must regenerate its own cortisol-producing capacity incrementally during this period. Each small reduction creates a small cortisol deficit that the adrenal cortex is gradually recovering its capacity to fill. If reductions are made too quickly during this phase, the adrenal axis cannot keep up and the patient develops symptoms of relative cortisol insufficiency (fatigue, nausea, arthralgias, hypotension) even though the underlying disease remains in remission. Morning serum cortisol monitoring and ACTH stimulation testing can guide the pace of this final phase.

• Option A: Option A is incorrect — Prednisone's conversion to prednisolone by 11β-HSD1 is not saturable at the dose range relevant to tapering (5 to 40 mg/day). This enzyme operates well within its capacity throughout the therapeutic dose range, and there is no clinically established nonlinearity in prednisone activation at low doses that would require smaller dose steps. The rationale for a slower final taper phase is entirely related to HPA axis recovery, not to prodrug activation kinetics.
• Option B: Option B is incorrect — While disease monitoring intervals are relevant to taper management, the pharmacological reason for slowing the pace at physiological-range doses is HPA axis recovery, not statistical considerations about percentage dose reductions per step. Monitoring intervals can be adjusted independently of dose step size, and this option does not address the fundamental endocrine physiology that governs the taper pace.
• Option C: Option C is incorrect — GR upregulation during corticosteroid exposure is a known regulatory phenomenon, but it does not produce a paradoxical increase in sensitivity to endogenous cortisol that causes rebound inflammation requiring continued low-dose steroid supplementation. Rebound inflammation during corticosteroid tapering reflects the return of the underlying disease activity, not a GR density effect. Furthermore, GR density normalizes within days after corticosteroid withdrawal, not over weeks.
• Option E: Option E is incorrect — There is no established threshold below which prednisone fails to suppress NF-κB in B lymphocytes such that autoantibody production "doubles with each 1 mg reduction." The pharmacodynamic relationship between prednisone dose and B cell NF-κB suppression is continuous and gradual, not a binary threshold phenomenon at 7.5 mg/day. The slow final taper phase is driven by HPA axis recovery requirements, not by B cell immunological relapse kinetics.